# US 2008/0313749 A1 · Binding Compounds, Immunogenic Compounds and Peptidomimetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0313749 A1
- Document ID: US20080313749A1
- Status: Published application
- Kind: A1
- Application number: 11/795,922
- Filed: 2006-01-24
- Published: 2008-12-18
- Earliest claimed: 2005-01-24
- Assignees: Pepscan Systems B.V.
- Inventors: Peter Timmerman; Wouter Cornelis Puijk; Jelle Wouter Slootstra; Evert Van Dijk; Robert Hans Meloen
- Web page: https://patentgrep.com/patent/US20080313749A1

## CPC

- G01N 33/6812: {Assays for specific amino acids}
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/5409: {IL-5}
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/7158: {for chemokines}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides means and methods for producing compounds suitable for testing for the presence and/or identification of an immunogenic compound and/or a binding compound of interest. Immunogenic compounds and compositions are also herewith provided, as well as peptidomimetics of members of the cystine-knot family.

## Claims

### Claim 1

A method for producing a compound that is suitable for testing for the presence and/or identification of an immunogenic compound and/or a binding compound, the method comprising:
selecting at least one amino acid residue within the primary sequence of at least one proteinaceous molecule, wherein said selected amino acid residue is at least two amino acid residues located from other selected amino acid residues, if any;
selecting at least one flanking sequence of at least one selected amino acid residue, which flanking sequence is located in the direction of the N-terminus and/or C-terminus of said at least one proteinaceous molecule, said flanking sequence having a length of between 2 and 48 amino acid residues;
producing a peptide comprising at least one of said flanking sequences and at least two groups capable of reacting with a scaffold, said peptide having a length of at least 4 and at most 50 amino acid residues; and
contacting said peptide with said scaffold in order to form at least two linkages between said peptide and said scaffold, wherein the formation of a linkage accelerates the formation of a consecutive linkage.

### Claim 2 (depends on 1)

The method according to claim 1, wherein at least two amino acid residues within the primary sequence of said at least one proteinaceous molecule are selected.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said peptide comprises at least two of said flanking sequences.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said peptide comprises a flanking sequence of a first selected amino acid residue and a flanking sequence of a second selected amino acid residue.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said peptide has a length of at most 25 amino acid residues.

### Claim 6 (depends on 1)

The method according to claim 1, wherein at least one of said selected amino acid residues within the primary sequence of said at least one proteinaceous molecule is a cysteine residue.

### Claim 7 (depends on 1)

The method according to claim 1, wherein at least one cysteine in at least one of said flanking sequences is replaced by another amino acid residue.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said at least two groups capable of reacting with a scaffold are identical.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said at least two groups capable of reacting with a scaffold are cysteine residues.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said scaffold comprises a heteroaromatic or aromatic molecule.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said scaffold comprises a halomethylarene.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said scaffold comprises a bis(bromomethyl)benzene, a tris(bromomethyl)benzene, a tetra(bromomethyl)benzene, or a derivative thereof.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the first and the last amino acid residues of said peptide are cysteines.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said peptide comprises the formula C(X)xC(X)y or C(X)yC(X)x, and wherein C is a cysteine residue, (X)x represents at least one of said flanking sequences and (X)y represents any sequence derived from said at least one proteinaceous molecule.

### Claim 15 (depends on 14)

The method according to claim 14 wherein C is a cysteine residue and (X)x and (X)y each represent at least one of said flanking sequences.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said peptide comprises at least three cysteine residues and at least two of said flanking sequences.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said peptide comprises the formula C(X)nC(S)y or C(X)yC(X)x and wherein C is a cysteine residue, (X)x represents at least one of said flanking sequences and (X)y represents any sequence derived from said at least one proteinaceous molecule.

### Claim 18 (depends on 17)

The method according to claim 17, wherein (X)x and (X)y each represent at least one of said flanking sequences.

### Claim 19 (depends on 1)

The method according to claim 1, wherein said peptide comprises the formula C(X)nC(G)nC(X)yC or C(X)yC(G)nC(X)nC and wherein C is a cysteine residue, (G)n represents a spacer, (X)x represents at least one of said flanking sequence and (X)y represents any sequence derived from said at least one proteinaceous molecule.

### Claim 20 (depends on 19)

The method according to claim 19 wherein (X)x and (X)y each represent at least one of said flanking sequences.

### Claim 21 (depends on 1)

The method according to claim 1, wherein said peptide comprises the formula C(X)xC(X)m(G)n(X)pC(X)yC and wherein C is a cysteine residue, (G)n represents a spacer, and (X)x, (X)m, (X)p and (X)y each represent at least one of said flanking sequences.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1-21 claim 1, wherein said peptide comprises the formula C(X)m(G)m(X)pC(X)q(G)r(X)sC(X)t(G)u(X)vC and wherein C is a cysteine residue, (G)n, (G)r and (G)q represent a spacer and (X)m, (X)p, (X)q, (X) s, (X)t and (X)v each represent at least one of said flanking sequences.

### Claim 23 (depends on 1)

The method according to claim 1, wherein said proteinaceous molecule is selected from the group consisting of the cysteine-knot family, a transmembrane protein, TNF-alpha, HGF-SF, FGF-beta, an interleukin, IL-5, a chemokine, a G-protein-coupled receptor, CCR4, CXCR5, IGF, LMF, endothelin-1, VIP, CGRP, PIF, EGF, TGF-alpha, the EGFR family, HER1, HER2/neu, HER3, HER4, p53, corticotrophin RF, ACTH, parathyroid hormone, CCK, substance P, NPY, GRP, neurotrophin, angiotensin-2, angiogenin, angiopoietin, neurotensin, SLCLC, SARS-derived protein, HIV-derived protein, papillomavirus-derived protein and FMDV.

### Claim 24 (depends on 1)

The method according to claim 1, wherein said at least one amino acid residue is selected from a surface-exposed region of said at least one proteinaceous molecule.

### Claim 25 (depends on 1)

The method according to claim 1, wherein said at least one amino acid residue is selected from a sequence of at least one transmembrane protein, said sequence comprising an extracellular domain, three flanking amino acid residues located in the direction of the N-terminus of said at least one transmembrane protein, and three flanking amino acid residues located in the direction of the C-terminus of said at least one transmembrane protein.

### Claim 26 (depends on 1)

The method according to claim 1, wherein at least two amino acid residues are selected from an SS-bridge sequence of said at least one proteinaceous molecule.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the two cysteines of said SS-bridge are located at position x and (x+n), wherein n>21, and wherein said amino acid residue is selected from a region of said SS-bridge sequence starting at amino acid position x+[(n−20)/2] and ending at amino acid position x+[(n+20)/2].

### Claim 28 (depends on 1)

The method according to claim 1, comprising producing at least two peptides of different length.

### Claim 29 (depends on 1)

The method according to claim 1, wherein said peptide is coupled to said scaffold in solution.

### Claim 30 (depends on 1)

A method for screening for the presence and/or identity of an immunogenic compound and/or a binding compound, the method comprising:
producing a plurality of compounds comprising different peptides with the method according to claim 1; and
testing whether at least one of said plurality of compounds specifically binds an antibody or a functional part, derivative or analogue thereof specific for said at least one proteinaceous molecule, or a T cell or a functional part, derivative or analogue thereof specific for said at least one proteinaceous molecule.

### Claim 31 (depends on 1)

A method for screening for the presence and/or identity of an immunogenic compound, the method comprising:
producing a plurality of compounds comprising different peptides with the method according to claim 1; and
testing whether at least one of said plurality of compounds is capable of eliciting an immune response in a non-human animal.

### Claim 32 (depends on 30)

The method according to claims 30, further comprising selecting an immunogenic compound and/or a binding compound of interest.

### Claim 33 (depends on 30)

The method according to claim 30, further comprising:
selecting an immunogenic compound and/or a binding compound of interest; and
producing an antibody or T cell or a functional part, derivative and/or analogue thereof capable of specifically binding said immunogenic compound.

### Claim 34 (depends on 30)

The method according to claim 30, further comprising identifying said immunogenic compound and/or binding compound.

### Claim 35 (depends on 1)

An immunogenic compound and/or a binding compound produced by the method according to claim 1.

### Claim 36 (depends on 1)

An immunogenic composition comprising an immunogenic compound produced by the method according to claim 1.

### Claim 37 (depends on 1)

An isolated antibody or T cell, or a functional part, derivative and/or analogue thereof, capable of specifically binding an immunogenic compound obtainable by the method according to claim 1.

### Claim 38 (depends on 1)

An array comprising an immunogenic compound obtainable by the method according to claim 1.

### Claim 39

A peptidomimetic of a member of the cystine-knot (growth factor) family, said peptidomimetic comprising:
a polypeptide derived from the amino acid sequence of the beta-3 hairpin (B3) loop of said cystine-knot (growth factor) family member, wherein two amino acid residues have been replaced by a first and a second cysteine residue in the polypeptide which cysteines are attached to each other via a scaffold, wherein:
said first scaffold-attached cysteine residue is introduced at position CysIV+p located p residues C-terminal from the position that corresponds to amino acid CysIV in the wild-type B3-loop, wherein 5≦p≦12;
said second scaffold-attached cysteine residue is introduced at position CysV-q located q residues N-terminal from the position that corresponds to amino acid CysV in the wild-type B3-loop, wherein 4≦q≦12 and wherein (p-q) is −3, −2, −1, 0, 1, 2 or 3; and
the length of said polypeptide is from amino acid at position CysIV+x to amino acid at position CysV+y, wherein −5≦x≦1 and 1≦y≦6 under the provision that x+y=−1, 0, 1 or 2.

### Claim 40 (depends on 39)

The peptidomimetic of claim 39, wherein the length of the polypeptide is from CysIV+1 to CysV+1, from CysIV-5 to CysV+6, from CysIV-3 to CysV+4, from CysIV-5 to CysV+4 or from CysIV-2 to CysV+4, preferably wherein the length of the polypeptide is from CysIV+1 to CysV+1, from CysIV-2 to CysV+4 or from CysIV-5 to CysV+4.

### Claim 41 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first and second cysteine correspond to positions CysIV+12 and CysV−10, or to CysIV+11 and CysV−10, CysIV+10 and CysV−8, CysIV+9 and CysV−8, CysIV+8 and CysV−6, CysIV+7 and CysV−5, CysIV+7 and CysV−6, CysIV+7 and CysV−4, CysIV+5 and CysV−4 or CysIV+6 and CysV−4, preferably to positions CysIV+10 and CysV−8, CysIV+7 and CysV−6 or CysIV+8 and CysV−6.

### Claim 42 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first and second cysteine correspond to positions CysIV+10 and CysV−8.

### Claim 43 (depends on 39)

The peptidomimetic of claim 39 wherein said scaffold comprises a (hetero)aromatic molecule, preferably a (hetero)aromatic molecule comprising at least two benzylic halogen substituents.

### Claim 44 (depends on 43)

The peptidomimetic of claim 43, wherein said scaffold is selected from the group consisting of ortho-, meta- and para-dihaloxylene, 1,2,4,5 tetra halodurene, meta-dibromoxyleen (m-T2) and 1,2,4,5 tetrabromodurene (T4).

### Claim 45 (depends on 39)

The peptidomimetic of claim 39, wherein the polypeptide length is from CysIV+1 to CysV+1 and wherein said scaffold is meta dibromoxylene or meta-dibromoxylene.

### Claim 46 (depends on 39)

The peptidomimetic of claim 39, wherein the polypeptide length is from CysIV−2 to CysV+4 and wherein said scaffold is 1,2,4,5 tetrahalodurene or 1,2,4,5 tetrabromodurene.

### Claim 47 (depends on 39)

The peptidomimetic of claim 39, wherein said member of the cystine-knot protein family is a member of the glycoprotein hormone-beta (GLHB) subfamily, the platelet-derived growth factor (PDGF) subfamily, the transforming growth factor (TGF) subfamily, the nerve growth factor (NGF) subfamily or the glycoprotein hormone-alpha (GLHA) subfamily.

### Claim 48 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first cysteine corresponds to amino acid position CysFV+10 and wherein the position of said second cysteine corresponds to position CysV−8, preferably wherein said polypeptide is derived from the B3-loop of a member of the GLHB subfamily, the PDGF subfamily or the TGF subfamily.

### Claim 49 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first cysteine corresponds to amino acid position CysIV+8 and wherein the position of said second cysteine corresponds to position CysV−6.

### Claim 50 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first cysteine corresponds to amino acid position CysIV+7 and wherein the position of said second cysteine corresponds to position CysV−6.

### Claim 51 (depends on 39)

The peptidomimetic of claim 39, wherein the position of said first cysteine corresponds to amino acid position CysIV+8 and wherein the position of said second cysteine corresponds to position CysV−6 and wherein said polypeptide is derived from the B3-loop of a VEGF protein.

### Claim 52

A peptidomimetic selected from the group of peptidomimetics consisting of the polypeptide TFKELVYETCRVPGAAHHADSLCTYPVATQAH (SEQ ID NO:31) attached to scaffold m-T2, the polypeptide KIQKTATFKELVYETCRVPGAAHHADSLCTYPVATQAHAGK (SEQ NO:32) attached to scaffold T4, the polypeptide TFKCLVYETVRVPGAAHHADSLYTYPVACQAH (SEQ ID NO:37) attached to scaffold m-T2, the polypeptide TFKELVYETCRVPGDAHHADSLCTYPVATQAH (SEQ ID NO:38) attached to scaffold m-T2, the polypeptide TFKELVYETCRVPGAAHHADSLCTYPVATQAH (SEQ ID NO:31) attached to scaffold T3, the polypeptide TFKELVYETCRVPGDAHHADKLCTYPVATQAH (SEQ ID NO:40) attached to scaffold m-T2, the polypeptide TFKELVYETCRVPGDAHKAIDSLCTYPVATQAH (SEQ ID NO:41) attached to scaffold m-T2, the polypeptide ESNCTMQIMRIKPHQGQHIGEMSCLQH (SEQ ID NO:42) attached to scaffold m-T2, the polypeptide EESNCTMQIMRIKPHQGQHIGEMSCLQHN (SEQ ID NO:43) attached to scaffold m-T2, the polypeptide NYRDVRFESCRLPGAPRGVNPVCSYAVALSAQ (SEQ ID NO:126) attached to scaffold m-T2, the polypeptide VVANYRDVRFESCRLPGAPRGVNPVCSYAVALSAQAAL (SEQ ID NO:35) attached to scaffold m-T2 and the polypeptide NYRDVRFESCRLPGCPRGVNPVCSYAVALSAQ
S
S
NYRDVRFESCRLPGCPRGVNPVCSYAVALSAQ (SEQ ID NO:44), attached to two scaffolds m-T2.

### Claim 53 (depends on 39)

A method for preparing peptidomimetic of claim 39, comprising:
providing a polypeptide and a scaffold and
contacting said polypeptide and scaffold under conditions that allow for the covalent attachment of said polypeptide to said scaffold.

### Claim 54 (depends on 39)

A composition comprising the peptidomimetic claim 39.

### Claim 55 (depends on 54)

The composition of claim 54, wherein said peptidomimetic is coupled to a carrier.

### Claim 56 (depends on 39)

An isolated antibody specifically reactive with the peptidomimetic of claim 39.

### Claim 57

(canceled)
